Protara Therapeutics, INC

Protara Therapeutics, Inc. reported the resignation of its Chief Medical Officer, Leonardo Viana Nicacio, M.D., effective June 26, 2026, with his responsibilities to be absorbed by existing leadership.

Protara Therapeutics held its Annual Meeting on June 12, 2026, with stockholders approving key proposals including director elections, auditor ratification, and amendments to increase authorized shares and allow officer exculpation.

Protara Therapeutics announced Q1 2026 financial results, highlighting progress in TARA-002 development for lymphatic malformations and bladder cancer, with cash reserves projected into 2028.

Protara verified a 68.0% six‑month complete response in 25 BCG‑unresponsive NMIBC patients, triggering the exercise window for $5.25 warrants through June 29, 2026.

Protara Therapeutics announced positive interim Phase 2 data for TARA-002 in non-muscle invasive bladder cancer, demonstrating compelling response rates and a favorable safety profile.

Protara Therapeutics, Inc. announced the completion of its public offering, including the full exercise of the underwriters' option, raising approximately $86.3 million in gross proceeds.

Protara Therapeutics reports increased R&D spending and a net loss for Q1 2026, while advancing its TARA-002 and IV Choline Chloride programs.

Protara Therapeutics reported an increased net loss in Q3 2025, driven by higher R&D expenses for its clinical programs, while highlighting positive interim data for TARA-002 and progress for IV Choline Chloride.

Protara Therapeutics reported increased net losses in Q2 2025 due to higher research and development expenses, while advancing its TARA-002 and IV Choline Chloride clinical programs.

Protara Therapeutics reports its Q1 2025 financial results, highlighting progress in its clinical programs for TARA-002 and IV Choline Chloride.

Protara Therapeutics reported its financial results for the third quarter of 2024, highlighting progress in its clinical programs for TARA-002 and IV Choline Chloride.

Protara Therapeutics introduces a new equity incentive plan and reports its financial results for the second quarter of 2024, highlighting ongoing clinical trials and financial activities.

Protara Therapeutics details its 2024 financial results and provides updates on its clinical development programs for TARA-002 and IV Choline Chloride.

Protara Therapeutics, a clinical-stage biopharmaceutical company, released its 2023 annual report, highlighting progress in its TARA-002 and IV Choline Chloride development programs while reporting a net loss.

Protara Therapeutics CEO and President Jesse Shefferman reported transactions involving company stock, including the acquisition of shares at $1.91 and the sale of shares at an average of $4.09.

Protara Therapeutics Director Richard S. Levy acquired 31,000 stock options with an exercise price of $3.94, vesting on June 15, 2027.

Michael Edward Solomon, a Director at Protara Therapeutics, Inc., acquired 31,000 stock options with an exercise price of $3.94.

Cynthia Smith, a Director at Protara Therapeutics, Inc., acquired stock options granting the right to buy 31,000 shares.

Protara Therapeutics Director Gregory Sargent acquired 31,000 stock options with an exercise price of $3.94, vesting in full on the first anniversary of the grant date.

Jane Huang, a Director at Protara Therapeutics, Inc., acquired 31,000 stock options with an exercise price of $3.94, vesting in full on June 15, 2027.

Protara Therapeutics schedules its 2025 Annual Meeting for June 11, seeking stockholder votes on director elections, auditor ratification, executive compensation, and an equity incentive plan amendment.

Protara Therapeutics is holding its annual meeting of stockholders on June 11, 2025, to vote on key proposals including the election of directors, ratification of the independent auditor, executive compensation, and an amendment to the equity incentive plan.

Protara Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 7, 2024, with proposals including the election of directors, ratification of the accounting firm, approval of executive compensation, and approval of equity incentive and employee stock purchase plans.

Protara Therapeutics announces its 2024 Annual Meeting of Stockholders to be held virtually on June 7, 2024, featuring proposals for director elections, auditor ratification, executive compensation, and equity incentive plan approvals.

Several entities associated with Millennium Management have reported a combined beneficial ownership of over 5% in Protara Therapeutics, Inc.

Janus Henderson Group plc has reported beneficial ownership of 5,207,011 shares, representing 9.6% of Protara Therapeutics, Inc.'s common stock, as of March 31, 2026.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported a 5.1% beneficial ownership stake in Protara Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 4.7% of Protara Therapeutics, Inc.'s common stock as of December 31, 2025.

Janus Henderson Group plc and its affiliate funds have reported an 11.0% beneficial ownership in Protara Therapeutics, Inc. common stock.

RA Capital Management and its affiliates have filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Protara Therapeutics, Inc. as of June 30, 2025.